The purpose of this research study is to see if adding the PARP inhibitor olaparib concurrently with SRS followed by immunotherapy (durvalumab) and chemotherapy will lead to better control of breast cancer that has spread to the brain better than the standard approach.
This study aims to treat your cancer and closely resembles routine care that would be received regardless of participating on a research study. To participate on the study, you will frequently meet with a member of the study team in addition to your oncology care team. The study involves blood collection for research purposes in addition to routine blood work, collection of stool for microbiome, HIV and Hepatitis testing, stereotactic radiosurgery with concurrent administration of Olaparib followed by adjuvant combination of Durvaluma and physician's choice.
Study medication
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
Colette Shen
LCCC - Clinical Trials
Clinical or Medical
Interventional
Brain, Head, Nervous System
Cancer (Brain and Other Nervous System, Breast)
20-2970